Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer [Gastrointestinal Cancer]
Conclusion
Regorafenib provides minimal incremental benefit at high incremental cost per QALY in the third-line management of metastatic colorectal cancer. The cost-effectiveness of regorafenib could be improved by the use of value-based pricing.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Goldstein, Ahmad, Chen, Ayer, Howard, Lipscomb, El-Rayes, Flowers Tags: Chemotherapy, Cost Effectiveness Gastrointestinal Cancer Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Gastroenterology | Health | Medicare